Clofarabine in Chronic Lymphocytic Leukemia

• Status: Completed
• Trial end date: 2004-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a dose-escalation study to determine the maximum tolerated dose and toxic effects of clofarabine in patients with chronic lymphocytic leukemia and other acute leukemias. Clofarabine is a synthesized hybrid nucleoside analog, which is believed to possess the better qualities of fludarabine and chlorodeoxyadenosine, the 2 most active agents against lymphoproliferative disorders. Thus, it is hoped that this drug will be more active and less toxic than similar drugs.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Treatments: Clofarabine

Criteria

Inclusion criteria:

• Diagnosis of chronic lymphocytic leukemia

• Diagnosis of other acute leukemia

• At least 2 weeks since prior chemotherapy, immunotherapy, and/or radiotherapy

• Recovered from toxic effects of prior therapy

• Bilirubin no greater than 2 mg/dL

• Creatinine no greater than 1.5 mg/dL

Exclusion criteria:

• Candidate for treatment of higher efficacy or priority

• Pregnant or nursing